Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. - Wikidata - wikimedia - TriplyDB

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

http://www.wikidata.org/entity/Q44396463

about

Insights into CYP2B6-mediated drug-drug interactions SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo Sarcomas and pharmacogenetics.Antimycotic drug discovery in the age of genomics.Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.Cytochrome P450 2C9-CYP2C9.Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma.Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.

P2860

Q28078857-991731A5-CCD4-40D5-94EC-ABB9F8CDFBBC Q34307873-0EDBEE31-E09B-45FD-A2BE-8B521EB6DF5A Q34457423-5AB7AA55-1C65-45BD-8ACD-A7B9423E7CD9 Q35647150-BF498733-2327-47F2-AEF9-CABA87633150 Q36249224-9649E221-54FC-4489-955C-540FCC91B98B Q36334753-136373BD-3C08-4B09-A9B7-38AC8A02DE06 Q36802054-1BFA3955-84BC-45D9-93B3-0027E8C2E624 Q37457715-82E3BF6C-542D-4698-A007-571F6821C24C Q37613529-5C98ACB8-DEFA-4480-9C64-3DF3CA6232B9 Q37691210-3D7323D2-499C-410C-B2B6-CCB000E79576 Q38271855-4119ED0B-7E91-4B63-BEF5-B2BC01C56A77 Q39701132-A1E7B751-3937-4064-AFA1-90CC97B60511 Q40605580-D89B287F-868D-4DD5-BCBC-B3992D7E9452 Q42794014-20489029-6D0E-42C1-BC1D-2A23B0E5F46E Q46221248-4BD75697-46E2-4423-8514-0910EE854C52 Q46975102-B841A6F2-656C-4464-BBE8-4CCD1153FCA5 Q48290223-85D97159-C851-43D3-A841-F727FC0E8088 Q49618000-9C10D1A8-0005-4D87-8AED-BB2A862C76D6 Q51144588-88625723-031A-40AF-BDA9-1E29D772F914 Q51399624-2D035CDA-064A-48A3-8D47-E9D3A7DA21F5 Q51573777-603BD983-4F81-4565-B35F-F01B409F51D0 Q55426998-9B632655-75B0-4C8E-A915-429F4D546AC0

P2860

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

http://www.wikidata.org/entity/Q44396463

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@en

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@nl

type

label

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@en

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@nl

prefLabel

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@en

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@nl

P1433

Q44396463-0349C873-1924-40E6-8AB4-DA0698F81F4D

P1476

Q44396463-39C2E7EA-5B1B-464A-B74C-6D2B256738E8

P2093

Q44396463-2F237554-B10C-4A9F-9599-0D8A4CBC131E

Q44396463-4D13455F-9AE0-489B-A16A-A266A533B9FF

Q44396463-98B13A61-9222-475D-ADB0-747A9482A1C9

Q44396463-B20AF254-CDC2-47B6-B2AA-33F86DA443F8

Q44396463-FCB686BE-30BC-4B00-9DD3-5C4CB723CCA8

P2860

Q44396463-028CB1D8-8651-4BBE-AF6B-923857D11DDC

Q44396463-21CD6696-76D6-4A1A-BBB6-E557100D7079

Q44396463-23B36389-D30D-4117-8085-FD8A9035472E

Q44396463-38419067-6351-4614-9204-E69CED0A5E09

Q44396463-4E474203-8E17-4D7A-97F3-DA3EE848E86F

Q44396463-55667CC2-A2BC-46D6-B079-7B7DA8418BB8

Q44396463-619A193A-CC9E-40EF-910B-686B4A86D41C

Q44396463-942204B1-2E5C-4281-BDD4-D767C8AB8D35

Q44396463-9C072053-5E52-4FDA-8F85-3CB37F405D66

Q44396463-ACE91C95-CDAB-430D-8F45-5F134E0021E4

P2888

Q44396463-67A2CE74-5348-41B5-83D6-83330A617881

P304

Q44396463-046910A4-E215-4FB0-BF42-EBF5126D5BB5

P31

Q44396463-AC0821B1-08BD-4B3A-B6E2-A28197966B9F

P356

Q44396463-A14E3F4C-4594-4EF4-98EA-26596187B1A7

P433

Q44396463-AE396BF0-4A0F-4EA8-B75E-A19C73762C41

P478

Q44396463-3932C0EA-A472-4042-92C9-35EB532CF5D0

P50

Q44396463-3AD989EA-F0AC-445C-AF74-6414C16A86CA

Q44396463-784B299A-8249-442D-98AF-FE4DC0B86CA7

Q44396463-84D1B52A-D144-4E08-B1E9-5D50EA34B3D4

P577

Q44396463-ABE06427-CB54-4324-AF2E-CB2D7B33E48F

P5875

Q44396463-2530181F-2D49-46F2-9A61-63D28AC0883A

P698

Q44396463-D00BE9A4-F7A6-42E4-9D51-27F2C483E3F3

P356

S00228-003-0590-6

P1433

European Journal of Clinical Pharmacology

P1476

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

@en

P2093

Gunnel Tybring

http://www.w3.org/2001/XMLSchema#string

Laimonas Griskevicius

http://www.w3.org/2001/XMLSchema#string

Marja-Liisa Dahl

http://www.w3.org/2001/XMLSchema#string

Mats Hidestrand

http://www.w3.org/2001/XMLSchema#string

Mia Sandberg

http://www.w3.org/2001/XMLSchema#string

P2860

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

Biochemistry and molecular biology of the human CYP2C subfamily

Metabolism and pharmacokinetics of oxazaphosphorines.

Pharmacogenetics and adverse drug reactions.

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma.

P2888

s00228-003-0590-6

P304

103-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-003-0590-6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Moustapha Hassan

P577

2003-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10813897

http://www.w3.org/2001/XMLSchema#string

P698

12684728

http://www.w3.org/2001/XMLSchema#string